Novel mutations support a role for Profilin 1 in the pathogenesis of ALS

Bradley N Smith, Caroline Vance, Emma L Scotter, Claire Troakes, Chun Hao Wong, Simon Topp, Satomi Maekawa, Andrew King, Jacqueline C Mitchell, Karan Lund, Ammar Al-Chalabi, Nicola Ticozzi, Vincenzo Silani, Peter Sapp, Robert H Brown, John E Landers, Safa Al-Sarraj, Christopher E Shaw

Research output: Contribution to journalArticlepeer-review

79 Citations (Scopus)
104 Downloads (Pure)


Mutations in the gene encoding profilin 1 (PFN1) have recently been shown to cause amyotrophic lateral sclerosis (ALS), a fatal neurodegenerative disorder. We sequenced the PFN1 gene in a cohort of ALS patients (n = 485) and detected 2 novel variants (A20T and Q139L), as well as 4 cases with the previously identified E117G rare variant (∼ 1.2%). A case-control meta-analysis of all published E117G ALS+/- frontotemporal dementia cases including those identified in this report was significant p = 0.001, odds ratio = 3.26 (95% confidence interval, 1.6-6.7), demonstrating this variant to be a susceptibility allele. Postmortem tissue from available patients displayed classic TAR DNA-binding protein 43 pathology. In both transient transfections and in fibroblasts from a patient with the A20T change, we showed that this novel PFN1 mutation causes protein aggregation and the formation of insoluble high molecular weight species which is a hallmark of ALS pathology. Our findings show that PFN1 is a rare cause of ALS and adds further weight to the underlying genetic heterogeneity of this disease.

Original languageEnglish
Pages (from-to)1602.e17-1602.e27
Number of pages11
JournalNeurobiology of Aging
Issue number3
Early online date31 Oct 2014
Publication statusPublished - Mar 2015


Dive into the research topics of 'Novel mutations support a role for Profilin 1 in the pathogenesis of ALS'. Together they form a unique fingerprint.

Cite this